Trial intelligence / Profile preview

Open-label Study of Neratinib with Intensive Loperamide Prophylaxis in Early Stage HER2+ Breast Cancer

2015-004374-15Phase 2Completed

Sponsor

Puma Biotechnology, Inc.

Start

Feb 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1